Non-Small Cell Lung Cancer Clinical Trials

Innovative Therapies for Non-Small Cell Lung Cancer

If you are looking for non-small cell lung cancer treatment, Massive Bio can assist you. Our advanced artificial intelligence (AI) platform will recommend treatment options through clinical trials tailored to your specific condition. Once you submit your information, our oncology experts will review your advanced Lung cancer case and contact you.

Understanding treatment options is crucial when facing locally advanced, inoperable, or metastatic Non-Small Cell Lung Cancer diagnosis. Our role is to link patients with a pioneering clinical trial dedicated to creating novel and targeted treatments. These therapies are tailor-made to tackle the specific hurdles posed by locally advanced or metastatic Lung cancer, and they are offered free of charge to those participating in the trial.

When you register for our matching service, we’ll help you find clinical trials for free that are a good fit for your situation.

Here’s how it works:

Diagnosis: If you have been diagnosed with non-small cell lung cancer, including stage 3 inoperable NSCLC or stage 4 NSCLC, you might qualify for participation in innovative and promising clinical trials.

What is the usual classification of Lung cancer?

• Non-Small Cell Lung Cancer (NSCLC): NSCLC accounts for about 80-85% of all lung cancer cases, with prognosis varying by stage; early-stage NSCLC has higher survival rates, while advanced stages have a poorer prognosis. Key biomarkers for NSCLC include EGFR, ALK, TP53, MDM2, PD-L1, and KRAS, which guide targeted and immunotherapy treatments. Clinical trials for NSCLC either mutated or non-mutated genes to be eligible for their trials.
• Small Cell Lung Cancer (SCLC): SCLC represents 10-15% of lung cancer cases and is known for its aggressive nature and rapid spread, resulting in a generally poorer prognosis. Biomarkers for SCLC include neuroendocrine markers (chromogranin A, synaptophysin, NSE), PD-L1, and MYC amplification. SCLC trials typically explore new chemotherapy regimens and treatments targeting neuroendocrine markers.

Patients with both NSCLC and SCLC can find numerous clinical trials offering access to the latest and most advanced treatments tailored to their specific cancer characteristics.

Subtypes of Non-Small Cell Lung Cancer (NSCLC)

Squamous Cell Carcinoma: Originates in the squamous cells lining the airways, commonly associated with a history of smoking and typically found in the central part of the lungs near the main airway (bronchi).

Non-Squamous Cell Carcinoma:

• Adenocarcinoma lung cancer starts in the cells that produce mucus in the outer part of the lungs. Is the most common lung cancer in non-smokers and is more often found in women. Clinical trials offering Adenocarcinoma Lung Cancer treatment often require specific genetic mutations for enrollment, as this subtype frequently harbors genetic mutations.
• Large Cell Carcinoma: Can appear in any part of the lung and tends to grow and spread quickly, making it a more aggressive subtype.
• Other Less Common Non-Squamous Types: Includes rare subtypes like sarcomatoid carcinoma and adenosquamous carcinoma, each with unique cellular characteristics and behaviors.

Most clinical trials for advanced non-squamous NSCLC, including Stage 3 non-squamous NSCLC or Stage 4 non-squamous NSCLC, focus on patients with unresectable tumors. These trials offer a crucial opportunity to explore innovative therapies for those with limited treatment options, motivating patients to enroll and potentially benefit from cutting-edge treatments

What is an Advanced Stage NSCLC?

Knowing the 2 main different NSCLC types, it is important to know that most clinical trials focus on discovering Advanced NSCLC treatments thats why is important to know that into two main stages belong to the definition based on extent of the disease:

• Locally advanced NSCLC (Stage 3 Lung Cancer): is characterized by the spread of cancer to nearby tissues and lymph nodes, but not to distant parts of the body. Trials aimed at Stage 3 Non Small Cell Lung Cancer focus on patients with unresectable tumors because these patients have limited treatment options and a higher need for innovative therapies to manage their disease.
• Metastatic NSCLC (Stage 4 Lung Cancer): is characterized by the spread of cancer to distant parts of the body, such as the brain, bones, liver, or other organs. Most trials for Stage 4 Non-Small Cell Lung Cancer focus on patients with unresectable tumors due to their limited treatment options and the urgent need for innovative therapies to manage the disease.

Clinical trials play a crucial role in advancing the treatment of both Stage 3 NSCLC trials and Stage 4 NSCLC trials (also known as Stage III NSCLC trials and Stage IV NSCLC trials respectively). They offer patients access to cutting-edge therapies that may provide better outcomes and improved quality of life.

Treated vs. Untreated Non-Small Cell Lung Cancer (NSCLC)

• Treated NSCLC is cancer that has been treated with surgery, chemotherapy, radiation, targeted therapy, or immunotherapy. These treatments are used to manage and control the disease. Some clinical trials may require patients to have received prior treatments to be eligible for innovative new therapies.
• Untreated NSCLC: Refers to Lung Cancer that has not yet received any form of oncologic treatment, including systemic therapies or specific medications. This can apply to any stage of the disease, from early to advanced stages.

Resectable vs. Unresectable Lung Cancer

• Resectable Lung Cancer: Refers to cancer that can be surgically removed, typically confined to the lungs and nearby lymph nodes without extensive spread. This generally includes Early (Stage I), Localized (Stage II) and some cases of Stage IIIA.
• Unresectable Lung Cancer: Refers to cancer that cannot be surgically removed due to its size, location, or extent of spread to other parts of the body. This usually includes stages IIIB and IV, and some cases of stage IIIA, requiring alternative treatments such as chemotherapy, radiation, or targeted therapy.

Clinical trials for unresectable NSCLC explore advanced therapies such as targeted drugs and immunotherapy, providing patients access to the latest treatments. These trials aim to improve survival rates and quality of life.

Enhancing Your Treatment Prospects with Genomic Testing

NGS Biomarkers and Their Importance in NSCLC

Next-Generation Sequencing (NGS) is crucial for identifying key biomarkers in Non-Small Cell Lung Cancer (NSCLC), which help guide personalized treatment and determine eligibility for clinical trials. These are some important biomarkers:

• EGFR (Epidermal Growth Factor Receptor): is a protein found on the surface of some cells in your body. It plays a key role in regulating cell growth and division. In certain types of lung cancer, the EGFR protein is mutated or overactive, causing cells to grow and divide uncontrollably, leading to tumor growth. Targeted therapies have been developed to specifically block the activity of EGFR thereby slowing down or stopping the cancer’s progression. This makes EGFR a crucial target in the treatment of cancers with these specific genetic characteristics.
• KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog): KRAS mutations drive cancer cell proliferation and are common in NSCLC.
• ALK (Anaplastic Lymphoma Kinase) Rearrangement Positive: ALK rearrangements lead to abnormal cell signaling and growth.
• ROS1 Rearrangement Positive: ROS1 rearrangements cause abnormal cell growth similar to ALK rearrangements. Trials focus on ROS1 inhibitors for these patients.
• BRAF V600E Mutation Positive: BRAF V600E mutations result in uncontrolled cell division.
• NTRK1/2/3 Gene Fusion Positive: NTRK gene fusions create abnormal proteins that drive cancer growth.
• METex14 Skipping Mutation Positive: MET exon 14 skipping mutations lead to prolonged MET signaling, promoting cancer growth.
• RET Rearrangement Positive: RET rearrangements activate abnormal cell signaling pathways.
• ERBB2 (HER2) Mutation Positive: HER2 mutations cause excessive cell growth and division.

IHC Biomarkers and Their Importance in NSCLC

Immunohistochemistry (IHC) biomarkers are crucial in diagnosing and determining the appropriate treatment for non-small cell lung cancer (NSCLC). Some of the most significant IHC biomarkers for the NSCLC treatment and relevant for clinical trials include:

• PD-L1 (Programmed Death-Ligand 1): is a protein expressed on the surface of cancer cells that binds to the PD-1 receptor on T-cells, turning off the immune response against the cancer. High PD-L1 expression suggests that the tumor may respond well to immunotherapies anti PD-L1 therapies.
• MMR (Mismatch Repair): MMR proteins are involved in the repair of DNA replication errors. Deficiency in MMR leads to microsatellite instability (MSI), which can result in increased mutation rates within tumors. MMR deficiency is associated with high levels of MSI (MSI-H), which can make tumors more responsive to immunotherapy.

Knowing this helps doctors decide which treatments to use and enhance the possibility of getting targeted treatment like the ones offered in clinical trials.

What are the benefits of clinical trials?

• Innovative Therapy: Clinical trial therapies represent the forefront of medical science and technology, tailored specifically to treat various forms of liver cancer (HCC treatment). These advanced treatments are designed for conditions like locally advanced and metastatic liver cancer.
• Personalized Match: We recognize that every patient is unique. That’s why we focus on pairing you with a treatment plan that aligns with your specific requirements and medical history.
• Expert Guidance: Throughout your journey, our experienced team of medical professionals will be by your side, providing guidance, support, and answering any questions you may have regarding your liver cancer treatment.

By signing up for our matching program, you’re taking an active role in exploring new possibilities and gaining access to an innovative therapy that can potentially transform your life.